Boston Scientific sees $25M hit to 2019 revenue from surgical mesh withdrawal

|About: Boston Scientific Corp... (BSX)|By:, SA News Editor

Boston Scientific (NYSE:BSX) discloses that it expects a $25M negative impact to this year's revenue from the FDA-mandated withdrawal of its Uphold LITE Support System and Xenform Soft Tissue Repair Matrix products used for transvaginal repair of pelvic organ prolapse.

Subscribe for full text news in your inbox